Pamela Carroll, a 1985 graduate of Saint Michael’s College, is pioneering the integration of artificial intelligence (AI) in biotechnology, focusing on previously "undruggable" disease drivers. Her career trajectory, which includes significant roles in both research and business, highlights the transformative potential of AI in drug discovery and development.
Carroll's journey began at the National Cancer Institute, where her fascination with cell biology took root. This interest propelled her through advanced studies and into a leadership role in biotech, particularly after the advent of AI technologies like AlphaFold. At Isomorphic Labs, she is part of a team that aims to revolutionize drug development by leveraging AI to simulate vast molecular interactions, thereby accelerating the discovery process and tackling complex disease targets.
She emphasizes that while AI has not yet fully realized its potential in drug development, it is poised to significantly enhance speed and reduce costs in the coming years. Carroll predicts that foundational models will allow for drug design within months rather than years, fundamentally changing the landscape of biotech innovation.
However, she also acknowledges the ethical complexities introduced by AI, particularly regarding data security and algorithmic bias. As AI tools become more integrated into biotech, ensuring transparency and equitable access to healthcare will be crucial. Carroll's insights underscore the importance of a multidisciplinary approach, combining scientific expertise with a deep understanding of business and ethics, to navigate the future of biotechnology effectively.